NeuroIntact is a medical‐device company focused on maintaining neurological intactness for individuals suffering brain injuries through its proprietary brain-cooling system, protected by a granted U.S. patent titled “System and method for cooling the brain of a human subject.” Building on an early, non-dilutive financing from the U.S. Marine Corps that supported initial R&D, the company is now advancing its technology toward broader clinical application in critical-care settings. The product aims to mitigate secondary brain damage by rapidly lowering brain temperature, addressing an unmet need in neuro-critical care. With the new capital, NeuroIntact plans to deepen research and development, enhance its existing cooling platform, and investigate complementary solutions for broader neurological protection. Funds will also be directed toward scaling operations and expanding market reach so the technology can serve a wider patient population. The company’s patent portfolio and specialized focus position it as an emerging player in the medical technology sector, though no revenue or user metrics have been publicly disclosed. Management expects the recent infusion to accelerate progress toward commercial deployment and improved outcomes for brain-injury patients.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025